Dr. Heymach on Nivolumab for Lung Cancer
In Partnership With:
John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses efficacy findings with nivolumab (Opdivo) results for patients with metastatic lung cancer.
John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses efficacy findings with nivolumab (Opdivo) results for patients with metastatic lung cancer.
There is now 5 years of follow-up for patients treated with nivolumab, explains Heymach. This is one of the first studies that demonstrated a positive result from immunotherapy for patients with metastatic lung cancer.
This is a significant step forward in the field, states Heymach. Patients are now becoming long-term survivors, making immunotherapy a viable treatment option.
